Peter Bruno, PhD
Assistant Professor
Urology
School of Medicine

Education & Training

Show all (2) Hide

• Ph.D. Biology Massachusetts Institute of Technology 06/2016
• B.S. Molecular Biology University of California, San Diego 06/2010

Websites

Show all (1) Hide

• Bruno Lab website (brunolabucsf.com)

Publications (22)

Top publication keywords:
Histocompatibility Antigens Class IOrganelle BiogenesisCarboplatinNeoplastic Stem CellsCell SurvivalRibosomesCoordination ComplexesPoly-ADP-Ribose Binding ProteinsCisplatinAntineoplastic AgentsOrganoplatinum CompoundsBenzothiazolesPhenanthrolinesCysteineNaphthyridines

• High-throughput, targeted MHC class I immunopeptidomics using a functional genetics screening platform.
  Nature biotechnology 2023 Bruno PM, Timms RT, Abdelfattah NS, Leng Y, Lelis FJN, Wesemann DR, Yu XG, Elledge SJ
• The primary mechanism of cytotoxicity of the chemotherapeutic agent CX-5461 is topoisomerase II poisoning.
  Proceedings of the National Academy of Sciences of the United States of America 2020 Bruno PM, Lu M, Dennis KA, Inam H, Moore CJ, Sheehe J, Elledge SJ, Hemann MT, Pritchard JR
• A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress.
  Nature medicine 2017 Bruno PM, Liu Y, Park GY, Murai J, Koch CE, Eisen TJ, Pritchard JR, Pommier Y, Lippard SJ, Hemann MT
• Using an RNAi Signature Assay To Guide the Design of Three-Drug-Conjugated Nanoparticles with Validated Mechanisms, In Vivo Efficacy, and Low Toxicity.
  Journal of the American Chemical Society 2016 Barnes JC, Bruno PM, Nguyen HV, Liao L, Liu J, Hemann MT, Johnson JA
• Versatile in vivo regulation of tumor phenotypes by dCas9-mediated transcriptional perturbation.
  Proceedings of the National Academy of Sciences of the United States of America 2016 Braun CJ, Bruno PM, Horlbeck MA, Gilbert LA, Weissman JS, Hemann MT

Show all (17 more) Hide

• The genomics revolution comes to the immunopeptidome.
  Genes and immunity 2023 Bruno PM
• Author Correction: Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer.
  Nature communications 2020 Qi R, Wang Y, Bruno PM, Xiao H, Yu Y, Li T, Lauffer S, Wei W, Chen Q, Kang X, Song H, Yang X, Huang X, Detappe A, Matulonis U, Pepin D, Hemann MT, Birrer MJ, Ghoroghchian PP
• Publisher Correction: Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer.
  Nature communications 2018 Qi R, Wang Y, Bruno PM, Xiao H, Yu Y, Li T, Lauffer S, Wei W, Chen Q, Kang X, Song H, Yang X, Huang X, Detappe A, Matulonis U, Pepin D, Hemann MT, Birrer MJ, Ghoroghchian PP
• Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer.
  Nature communications 2017 Qi R, Wang Y, Bruno PM, Xiao H, Yu Y, Li T, Lauffer S, Wei W, Chen Q, Kang X, Song H, Yang X, Huang X, Detappe A, Matulonis U, Pepin D, Hemann MT, Birrer MJ, Ghoroghchian PP
• Aneuploid Cell Survival Relies upon Sphingolipid Homeostasis.
  Cancer research 2017 Tang YC, Yuwen H, Wang K, Bruno PM, Bullock K, Deik A, Santaguida S, Trakala M, Pfau SJ, Zhong N, Huang T, Wang L, Clish CB, Hemann MT, Amon A
• Induction of Necroptosis in Cancer Stem Cells using a Nickel(II)-Dithiocarbamate Phenanthroline Complex.
  Chemistry (Weinheim an der Bergstrasse, Germany) 2017 Flamme M, Cressey PB, Lu C, Bruno PM, Eskandari A, Hemann MT, Hogarth G, Suntharalingam K
• The breast cancer stem cell potency of copper(ii) complexes bearing nonsteroidal anti-inflammatory drugs and their encapsulation using polymeric nanoparticles.
  Dalton transactions (Cambridge, England : 2003) 2016 Eskandari A, Boodram JN, Cressey PB, Lu C, Bruno PM, Hemann MT, Suntharalingam K
• The Potent Inhibitory Effect of a Naproxen-Appended Cobalt(III)-Cyclam Complex on Cancer Stem Cells.
  Chembiochem : a European journal of chemical biology 2016 Cressey PB, Eskandari A, Bruno PM, Lu C, Hemann MT, Suntharalingam K
• Mechanistic Studies of the Anticancer Activity of An Octahedral Hexanuclear Pt(II) Cage.
  Inorganica chimica acta 2016 Zheng YR, Suntharalingam K, Bruno PM, Lin W, Wang W, Hemann MT, Lippard SJ
• Correction to "A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy".
  Journal of the American Chemical Society 2016 Awuah SG, Zheng YR, Bruno PM, Hemann MT, Lippard SJ
• Breast Cancer Stem Cell Potent Copper(II)-Non-Steroidal Anti-Inflammatory Drug Complexes.
  Angewandte Chemie (International ed. in English) 2016 Boodram JN, Mcgregor IJ, Bruno PM, Cressey PB, Hemann MT, Suntharalingam K
• A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy.
  Journal of the American Chemical Society 2015 Awuah SG, Zheng YR, Bruno PM, Hemann MT, Lippard SJ
• Necroptosis-inducing rhenium(V) oxo complexes.
  Journal of the American Chemical Society 2015 Suntharalingam K, Awuah SG, Bruno PM, Johnstone TC, Wang F, Lin W, Zheng YR, Page JE, Hemann MT, Lippard SJ
• A breast cancer stem cell-selective, mammospheres-potent osmium(VI) nitrido complex.
  Journal of the American Chemical Society 2014 Suntharalingam K, Lin W, Johnstone TC, Bruno PM, Zheng YR, Hemann MT, Lippard SJ
• Bidentate ligands on osmium(VI) nitrido complexes control intracellular targeting and cell death pathways.
  Journal of the American Chemical Society 2013 Suntharalingam K, Johnstone TC, Bruno PM, Lin W, Hemann MT, Lippard SJ
• Predicting cancer drug mechanisms of action using molecular network signatures.
  Molecular bioSystems 2013 Pritchard JR, Bruno PM, Hemann MT, Lauffenburger DA
• Defining principles of combination drug mechanisms of action.
  Proceedings of the National Academy of Sciences of the United States of America 2012 Pritchard JR, Bruno PM, Gilbert LA, Capron KL, Lauffenburger DA, Hemann MT